Skip to main content
main-content

01.12.2017 | Research article | Ausgabe 1/2017 Open Access

BMC Medicine 1/2017

What is the association of hypothyroidism with risks of cardiovascular events and mortality? A meta-analysis of 55 cohort studies involving 1,898,314 participants

Zeitschrift:
BMC Medicine > Ausgabe 1/2017
Autoren:
Yu Ning, Yun J. Cheng, Li J. Liu, Jaskanwal D. S. Sara, Zhi Y. Cao, Wei P. Zheng, Tian S. Zhang, Hui J. Han, Zhen Y. Yang, Yi Zhang, Fei L. Wang, Rui Y. Pan, Jie L. Huang, Ling L. Wu, Ming Zhang, Yong X. Wei
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​s12916-017-0777-9) contains supplementary material, which is available to authorized users.
Abbreviations
AF
Atrial fibrillation
BMI
Body mass index
CI
Confidence interval
FT4
Free tetraiodothyronine
HF
Heart failure
HR
Hazard ratio
IHD
Ischemic heart disease
IPD
Individual participant data
IRR
Incidence rate ratio
MI
Myocardial infarction
OHypo
Overt hypothyroidism
OR
Odds ratio
RR
Relative risk
RT
Replacement therapy
SCH
Subclinical hypothyroidism
TSH
Thyroid-stimulating hormone

Background

Thyroid hormones have wide effects on the body and play an important role in homeostasis of the cardiovascular system [1]. Abnormal thyroid function has health consequences for the general public. Patients with hypothyroidism have an increased risk of cardiovascular abnormalities, such as accelerated atherosclerosis [2].
Whether hypothyroidism (“hypothyroidism” refers to the combination of subclinical hypothyroidism (SCH) and overt hypothyroidism (OHypo) in this article), SCH or OHypo, is an independent risk factor for cardiovascular events or mortality has conflicting opinions. It is also conflicting whether adults with hypothyroidism and preexisting cardiovascular disease might be at particularly high cardiovascular risk [35]. Although there have been meta-analyses and even individual participant data (IPD) meta-analyses on the subject so far [610], they have been restricted to patients with SCH. Moreover, many additional cohort studies have been published since. Therefore, a comprehensive updated meta-analysis is warranted.

Methods

Search strategy

This meta-analysis follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Checklist (Additional file 1). We searched PubMed and Embase from inception to 29 February 2016, using the following text and key words, both as MeSH terms and text words: hypothyroidism, subclinical hypothyroidism, thyroid diseases, thyroid function, thyroid status, coronary heart diseases, ischemic heart diseases, myocardial infarction, coronary atherosclerosis, cardiovascular diseases, death, mortality, heart failure, stroke, atrial fibrillation, arrhythmia, peripheral artery diseases. We searched articles published in any language and screened references from these studies to identify other relevant studies. YN and YJC performed the literature search independently. Differences were resolved by discussion.

Inclusion criteria

To minimize differences, studies were required (1) to measure thyroid function and follow persons prospectively; to assess ischemic heart disease (IHD), mortality or other cardiovascular events; and to provide risk estimates or sufficient data to calculate risk estimates associated with hypothyroidism compared with euthyroidism; (2) to be cohort studies published as original articles; and (3) to be independent. For multiple publications of the same study design, we included the estimates from the most recent or informative reports.

Data collection and analysis

Data were extracted by one reviewer (YN) and independently checked by another three reviewers (YJC, LJL, and HJH); the data included the first author’s name, publication year, location, female proportion, mean age, mean follow-up years, sample size, study design, study population, number of cardiovascular events and mortality, risk estimates, categories and definitions of hypothyroidism, thyroid treatment, and covariates adjusted for in the multivariable analyses. Primary authors were contacted by email if the study did not provide the data needed. We used the Newcastle-Ottawa scale to evaluate the quality of cohort studies. In the present analyses, we regarded a study awarded a total score of ≥6 as a high-quality study [11].
Hypothyroidism was categorized as SCH and OHypo. Their definitions varied across studies. Generally, SCH was defined as elevated thyroid-stimulating hormone (TSH) levels and normal free tetraiodothyronine (FT4) levels. OHypo was defined as elevated TSH but decreased FT4 levels [5]. In this analysis, hypothyroidism refers to the combination of SCH and OHypo. The primary exposure of interest is hypothyroidism (i.e., participants with an increased TSH level regardless of FT4 level).
The primary outcomes were IHD, cardiac mortality, cardiovascular mortality, and all-cause mortality as defined by International Classification of Diseases-10-CM (ICD-10-CM) diagnosis codes. For IHD (I20–I25), we included angina pectoris, myocardial infarction (MI), and chronic ischemic heart disease. For cardiac mortality, we included deaths caused by IHD, progressive heart failure (HF), arrhythmia, or cardiac arrest (I20–I25; I44–I50). For cardiovascular mortality, we included deaths from diseases of the circulatory system (I00–I99). We used both cardiac and cardiovascular mortality for the following two reasons: first, both of them had been discussed in different meta-analyses previously; second, the related data of both outcomes were available from considerable original cohort studies. Therefore, it is necessary to analyze both of them in one meta-analysis to achieve comprehensive comparison to the previous meta-analyses. The secondary outcomes were stroke, HF, MI, atrial fibrillation (AF), and total cardiovascular events.

Statistical analyses

The available risk estimates that were extracted were mostly hazard ratios (HRs), while those in partial studies were rate ratios (RRs) [1215], incidence rate ratios (IRRs) [16, 17], or odds ratios (ORs) [18]. We used the most comprehensively adjusted estimates in the reports. When risk estimates and confidence intervals (CIs) were not provided [1921], we calculated RRs and CIs from available data by using the Woolf method in Stata version 12.1 software (used for all analyses) [9, 22]. Since the absolute risk of IHD, cardiac mortality, cardiovascular mortality, all-cause mortality, stroke, HF, MI, AF, or total cardiovascular events is low, the four measures of association are expected to yield similar estimates of RR [23, 24]. Consequently, we estimated the pooled RRs and their CIs by using metan commands and random effects models based on the variance model developed by DerSimonian and Laird [9, 25]. We calculated the I 2 statistic to assess heterogeneity among studies. The formula is {(Q-df)/Q × 100%}, where Q is the chi-squared statistic and df is its degrees of freedom [26]. We use the following criteria: I 2 < 50%, low heterogeneity; 50–75%, moderate heterogeneity; >75%, high heterogeneity [26, 27].
Several predefined subgroup analyses were intended to explore potential sources of heterogeneity in primary outcomes (metan command); where enough studies (n ≥ 10) [28] were available, meta-regressions were conducted (metareg command). Specifically, we intended to conduct subgroup analyses by hypothyroid states and by study population to clarify whether adults with hypothyroidism and preexisting cardiovascular disease were at particularly high cardiovascular risk. Given previous findings of the possible protective effect of SCH in oldest old people [29], we intended to conduct subgroup analyses by mean age of populations. Predefined sensitivity analyses were performed to test the robustness of the results (metan command). When I 2 ≥ 50% (moderate or high heterogeneity), we used the hetred command in Stata to evaluate the change in between-study heterogeneity as one or more outlier studies were excluded from the calculations, a method which was developed by Patsopoulos [30]. If available, we intended to perform additional subgroup analyses of main outcomes by TSH levels (TSH ≥ 10.0 and TSH < 10.0 mIU/L) in SCH.
If there were at least 10 studies included in each outcome of the meta-analysis, publication bias or small study bias was assessed with a funnel plot by using Egger’s regression asymmetry test (metabias6 command) [31, 32]. Statistical tests were two-sided and used a significance level of P < 0.05.

Results

Search results

Of 3889 reports identified, we excluded 3775 studies that were unrelated to our theme and 59 studies after detailed evaluation. Fifty-five cohort studies met the inclusion criteria. Figure 1 shows details of the study selection.
Additional file 2: Table S1 shows the main characteristics of the 55 included studies. Thirty-two studies were population-based studies. Twenty-three studies were convenience samples (i.e., particular patient groups), of which 14 studies comprised cardiac patients. Nineteen studies analyzed with all hypothyroidism, 34 with SCH, and 8 with OHypo. Cohort studies included in each outcome are mainly prospective and mostly from Europe or North America. Thirty-seven of the 55 studies were published in the last 5 years (2012–2016). Of the 55 cohort studies, 49 studies were awarded a total score of ≥6 (Additional file 2: Table S2).
Additional file 2: Table S3 shows detailed information on adjustments in risk estimates of each cohort study. Most risk estimates were adjusted for age (47 studies) and sex (40 studies), which are well known as potential confounders of both thyroid disease status and risk of cardiovascular events. Forty studies (72.7%) reported an adjusted estimate for at least one of the main cardiovascular risk factors (body mass index (BMI), smoking, cholesterol, hypertension, and diabetes). Seven studies’ risk estimates were adjusted for replacement therapy (RT).

Hypothyroidism and IHD

Thirteen studies with 615,596 individuals and 16,862 events analyzed with IHD. Twelve studies’ risk estimates were adjusted for age, ten adjusted for sex, and more than half adjusted for smoking, BMI, hypertension, or diabetes, but only three adjusted for RT.
Overall, patients with hypothyroidism experienced a higher risk of IHD compared to euthyroidism (RR: 1.13; 95% CI: 1.01–1.26), with evidence of low heterogeneity (I 2: 40.2%; P = 0.066; Fig. 2). Table 1 shows the results of sensitivity analyses. Risk estimates changed little after analyzing with fixed effects models, or after inclusion of studies with ≥10,000 participants, studies without RT at baseline, or high-quality studies. No publication bias was found (Egger test: P = 0.65; Additional file 2: Figure S1).
Table 1
Sensitivity analyses of pooled RRs of cardiovascular events and mortality
 
IHD
Cardiac mortality
Cardiovascular mortality
N
studies
RR
(95% CI)
I 2
P
valuea
N
studies
RR
(95% CI)
I 2
P
valuea
N
studies
RR
(95% CI)
I 2
P
valuea
Statistical model
 Random effects
13
1.13 (1.01–1.26)
40.2%
0.07
7
1.96 (1.38–2.80)
66.2%
0.007
17
1.11 (0.97–1.28)
11.1%
0.32
 Fixed effects
13
1.12 (1.05–1.20)
-
-
7
1.73 (1.45–2.08)
-
-
17
1.11 (0.99–1.25)
-
-
Analyses with
 Large cohortb
3
1.11 (1.01–1.21)
0.0%
0.70
1
1.38 (1.03–1.84)
-
-
2
1.50 (1.05–2.14)
0.0%
0.52
 No RT at baseline
7
1.11 (1.03–1.20)
0.0%
0.49
6
2.22 (1.52–3.24)
60.6%
0.03
8
1.13 (0.95–1.35)
5.6%
0.39
 High-quality studiesc
11
1.13 (1.03–1.25)
31.5%
0.15
5
1.77 (1.23–2.54)
70.3%
0.009
14
1.11 (0.92–1.32)
23.7%
0.20
Analyses except
 Outlier studyd
13
1.13 (1.01–1.26)
40.2%
0.07
5
1.55 (1.15–2.08)
37.9%
0.17
17
1.11 (0.97–1.28)
11.1%
0.32
 Calculated RRse
12
1.12 (1.01–1.24)
38.3%
0.09
7
1.96 (1.38–2.80)
66.2%
0.007
16
1.11 (0.96–1.28)
16.3%
0.27
 
All-cause mortality
Stroke
HF
N
studies
RR
(95% CI)
I 2
P
valuea
N
studies
RR
(95% CI)
I 2
P
valuea
N
studies
RR
(95% CI)
I 2
P
valuea
Statistical model
 Random effects
40
1.25 (1.13–1.39)
86.9%
<0.001
9
1.09 (0.96–1.24)
52.3%
0.03
8
1.13 (0.98–1.30)
54.8%
0.03
 Fixed effects
40
1.20 (1.16–1.23)
-
-
9
1.03 (0.97–1.09)
-
-
8
1.07 (1.00–1.14)
-
-
Analyses with
 Large cohortb
7
1.18 (0.94–1.48)
97.0%
<0.001
2
1.01 (0.86–1.19)
86.3%
0.007
2
1.03 (0.95–1.11)
0.0%
0.87
 No RT at baseline
20
1.32 (1.10–1.59)
92.0%
<0.001
1
0.93 (0.85–1.01)
-
-
4
1.02 (0.95–1.09)
0.0%
0.90
 High-quality studiesc
34
1.25 (1.11–1.39)
88.6%
<0.001
9
1.09 (0.96–1.24)
52.3%
0.03
6
1.17 (0.99–1.39)
66.3%
0.01
Analyses except
 Outlier studyd
32
1.30 (1.22–1.39)
26.4%
0.09
8
1.12 (1.04–1.21)
0.0%
0.43
7
1.07 (0.94–1.21)
34.4%
0.16
 Calculated RRse
38
1.27 (1.15–1.41)
87.1%
<0.001
9
1.09 (0.96–1.24)
52.3%
0.03
8
1.13 (0.98–1.30)
54.8%
0.03
 
MI
AF
Total cardiovascular events
N
studies
RR
(95% CI)
I 2
P
valuea
N
studies
RR
(95% CI)
I 2
P
valuea
N
studies
RR
(95% CI)
I 2
P
valuea
Statistical model
 Random effects
7
1.15 (1.05–1.25)
0.0%
0.43
4
1.02 (0.71–1.46)
70.6%
0.02
8
1.16 (0.97–1.38)
73.4%
<0.001
 Fixed effects
7
1.15 (1.05–1.25)
-
-
4
1.02 (0.85–1.21)
-
-
8
1.06 (1.01–1.11)
-
-
Analyses with
 Large cohortb
2
1.12 (1.02–1.24)
0.0%
0.55
2
1.09 (0.59–2.02)
89.9%
0.002
2
1.15 (0.84–1.57)
92.2%
<0.001
 No RT at baseline
4
1.12 (1.02–1.23)
0.0%
0.57
1
0.80 (0.62–1.03)
-
-
3
1.12 (0.80–1.56)
25.2%
0.26
 High-quality studiesc
7
1.15 (1.05–1.25)
0.0%
0.43
3
1.06 (0.66–1.70)
79.9%
0.007
8
1.19 (0.99–1.43)
73.5%
<0.001
Analyses except
 Outlier studyd
7
1.15 (1.05–1.25)
0.0%
0.43
3
0.83 (0.67–1.03)
0.0%
0.85
7
1.28 (1.16–1.40)
0.0%
0.50
 Calculated RRse
6
1.14 (1.05–1.24)
0.0%
0.58
4
1.02 (0.71–1.46)
70.6%
0.02
8
1.16 (0.97–1.38)
73.4%
<0.001
AF atrial fibrillation, CI confidence interval, HF heart failure, IHD ischemic heart disease, MI myocardial infarction, RR relative risk, RT replacement therapy
a P value for heterogeneity
bLarge cohort studies with >10,000 population
cHigh-quality studies with a total score of ≥6
dOutlier studies found by sensitivity analyses (hetred command); there were 2 for cardiac mortality, 8 for all-cause mortality, 1 for stroke, 1 for HF, 1 for AF, and 1 for total cardiovascular events
eThree cohort studies did not report the estimates: Aho et al. [21] (cardiovascular mortality), Bai et al. [20] (IHD, all-cause mortality, MI), Parle et al. [19] (all-cause mortality)
A priori subgroup analyses were conducted across key study characteristics (Table 2); higher risk of IHD associated with hypothyroidism was consistently observed in some of these analyses. The estimates did not differ significantly between population-based and convenience samples studies. There was no significantly higher risk of IHD events in cardiac patients with hypothyroidism. However, this should be considered seriously for only three studies included. The estimates also did not differ significantly across other subgroups. In additional subgroup analyses by TSH levels in patients with SCH compared with euthyroidism, we observed a significantly higher risk of IHD in SCH with TSH level ≥10.0 mIU/L (RR: 1.32; 95% CI: 1.00–1.74; Additional file 2: Table S4). Univariate meta-regressions showed that these a priori factors did not affect the overall effects (Table 3).
Table 2
Subgroup and heterogeneity analyses of pooled RRs of primary outcomes
Factors
IHD
Cardiac mortality
N
studies
Events/participants
RR
(95% CI)
I 2
P
valuea
N
studies
Events/participants
RR
(95% CI)
I 2
P
valuea
Degrees of hypothyroidism
 All hypothyroidism
4
13,444/593,499
1.13 (1.04–1.23)
0.0%
Reference
2
282/2836
1.83 (0.72–4.62)
90.0%
0.75
 SCH
8
3400/21,623
1.12 (0.89–1.42)
55.8%
0.74
5
819/32,086
2.00 (1.34–2.97)
47.8%
Reference
 OHypo
1
18/474
2.54 (0.87–7.41)
-
0.30
-
-
-
-
-
Study population
 Convenience sample
4
1406/8946
1.08 (0.66–1.79)
58.2%
0.73
5
398/6595
2.33 (1.39–3.91)
70.7%
Reference
  Cardiac patientsb
3
1277/8149
1.15 (0.68–1.94)
67.7%
-
4
393/5596
2.22 (1.28–3.83)
76.5%
-
 Population-based
9
15,456/606,650
1.12 (1.00–1.25)
36.8%
Reference
2
703/28,327
1.43 (1.10–1.86)
0.0%
0.33
Mean age
 ≥80 years
-
-
-
-
 
-
-
-
-
-
 65–79 years
8
3417/20,298
1.06 (0.89–1.27)
37.4%
0.45
2
236/3077
1.91 (0.61–5.93)
82.3%
0.68
 <65 years
5
13,445/595,298
1.19 (1.02–1.39)
51.0%
Reference
5
865/31,845
2.07 (1.39–3.07)
61.8%
Reference
Location
 Europe
7
13,907/600,542
1.10 (0.95–1.26)
31.7%
0.23
4
814/31,087
1.91 (1.28–2.86)
52.8%
0.26
 North America
4
2675/12,727
1.08 (0.95–1.24)
15.2%
0.22
1
205/2430
1.14 (0.76–1.71)
-
Reference
 Asia
1
18/474
2.54 (0.87–7.41)
-
Reference
2
82/1405
3.02 (2.00–4.56)
0.0%
0.10
 Oceania
1
262/1853
1.80 (1.20–2.70)
-
0.63
-
-
-
-
-
Female proportion
 ≥50%
9
15,773/610,042
1.07 (0.98–1.18)
19.9%
0.08
3
708/29,326
1.47 (1.12–1.94)
2.3%
Reference
 <50%
4
1089/5554
1.47 (1.04–2.07)
40.9%
Reference
4
393/5596
2.22 (1.28–3.83)
76.5%
0.52
Mean follow-up
 ≥10 years
5
3615/45,383
1.18 (0.98–1.42)
55.4%
Reference
3
708/29,326
1.47 (1.12–1.94)
2.3%
Reference
 5–10 years
2
11,491/557,482
1.13 (1.02–1.25)
0.0%
0.73
-
-
-
-
-
 <5 years
6
1756/12731
1.07 (0.75–1.53)
53.9%
0.59
4
393/5596
2.22 (1.28–3.83)
76.5%
0.52
Factors
Cardiovascular mortality
All-cause mortality
N
studies
Events/participants
RR
(95% CI)
I 2
P
valuea
N
studies
Events/participants
RR
(95% CI)
I 2
P
valuea
Degrees of hypothyroidism
 All hypothyroidism
5
2724/20,707
0.99 (0.70–1.39)
42.0%
0.35
21
98,621c/876,811
1.21 (1.07–1.37)
87.6%
0.51
 SCH
12
2549/137,310
1.15 (1.00–1.32)
0.0%
Reference
18
13,529/159,104
1.32 (1.13–1.54)
65.9%
Reference
 OHypo
-
-
-
-
-
1
6/474
1.78 (0.21–14.98)
-
0.80
Study population
 Convenience sample
5
1454/12,229
1.15 (0.95–1.39)
0.0%
0.70
20
9004c/54,577
1.45 (1.27–1.66)
63.4%
0.009
  Cardiac patientsb
2
1333/9820
1.10 (0.83–1.45)
0.0%
-
13
4643c/38,219
1.51 (1.26–1.81)
65.7%
-
 Population-based
12
3819/145,788
1.08 (0.86–1.36)
33.3%
Reference
20
103,152/981,812
1.10 (0.95–1.28)
91.7%
Reference
Mean age
 ≥80 years
1
87/539
0.55 (0.33–0.93)
-
0.004
3
6216/18,267
1.05 (0.55–1.98)
95.2%
Reference
 65–79 years
11
2799/22,989
1.08 (0.94–1.23)
0.0%
0.04
20
9706/49,057
1.15 (1.03–1.29)
34.7%
0.73
 <65 years
5
2387/134,489
1.53 (1.16–2.01)
0.0%
Reference
17
96,234c/969,065
1.38 (1.19–1.60)
89.3%
0.22
Location
 Europe
7
1807/13,446
0.96 (0.74–1.23)
33.4%
0.045
19
92,477/847,659
1.09 (0.95–1.26)
83.2%
0.92
 North America
5
2544/24,417
1.08 (0.90–1.29)
0.0%
0.097
10
8176c/40,891
1.26 (1.12–1.41)
54.5%
0.50
 Asia
4
731/118,301
1.72 (1.13–2.62)
0.0%
Reference
10
10,671/143,981
1.75 (1.42–2.15)
60.1%
0.07
 Oceania
1
191/1853
1.50 (0.90–2.50)
-
0.70
1
832/3858
1.06 (0.86–1.31)
-
Reference
Female proportion
 ≥50%
12
3814/149,254
1.06 (0.87–1.29)
29.5%
Reference
22
103,550/990,510
1.13 (0.97–1.31)
91.1%
Reference
 <50%
5
1459/8763
1.23 (0.96–1.58)
0.0%
0.35
18
8606c/45,879
1.42 (1.25–1.63)
65.8%
0.03
Mean follow-up
 ≥10 years
7
3338/139,867
1.21 (0.98–1.50)
16.2%
0.12
9
14,896/165,332
1.25 (0.98–1.59)
89.7%
0.44
 5–10 years
5
399/4517
1.19 (0.94–1.52)
0.0%
0.20
13
88,149c/822,913
1.10 (0.92–1.32)
85.8%
Reference
 <5 years
5
1536/13,633
0.88 (0.63–1.23)
34.0%
Reference
18
9111c/48,144
1.37 (1.19–1.58)
72.7%
0.09
CI confidence interval, IHD ischemic heart disease, OHypo overt hypothyroidism, RR relative risk, SCH subclinical hypothyroidism
aP values indicate whether the pooled estimate in each subgroup differs from a nominated reference subgroup
bStudies with cardiac patients were included in convenience sample studies
cTwo cohort studies by McQuade et al. [45] and Mitchell et al. [46] did not provide the number of all-cause mortality events; we contacted the authors by email but didn’t get a reply
Table 3
Univariate meta-regression of hypothyroidism on IHD events and mortality
Variable
IHD
Cardiovascular mortality
All-cause mortality
N
studies
Scale
Exp(b)a
(95% CI)
P valueb
N
studies
Scale
Exp(b)a
(95% CI)
P valueb
N
studies
Scale
Exp(b)a
(95% CI)
P valueb
Degrees of hypothyroidism
 SCH
8
Per unit
0.97 (0.77, 1.22)
0.74
12
Per unit
Reference
-
18
Per unit
Reference
-
 OHypo
1
 
2.25 (0.44, 11.36)
0.30
0
 
-
-
1
 
1.36 (0.12, 15.24)
0.80
 All
4
 
Reference
-
5
 
0.86 (0.61, 1.20)
0.35
21
 
0.93 (0.73, 1.17)
0.51
Study population
13
Per unit
1.05 (0.77, 1.43)
0.73
17
Per unit
1.06 (0.75, 1.50)
0.70
40
Per unit
1.32 (1.08, 1.62)
0.009
Mean age
 ≥80 years
0
Per unit
-
-
1
Per unit
0.36 (0.19, 0.69)
0.004
3
Per unit
Reference
-
 65–79 years
8
 
0.91 (0.70, 1.19)
0.45
11
 
0.70 (0.50, 0.98)
0.04
20
 
1.07 (0.72, 1.59)
0.73
 <65 years
5
 
Reference
-
5
 
Reference
-
17
 
1.27 (0.86, 1.87)
0.22
Location
 Europe
7
Per unit
0.44 (0.10, 1.86)
0.23
7
Per unit
0.57 (0.33, 0.99)
0.045
19
Per unit
1.03 (0.62, 1.71)
0.92
 North America
4
 
0.43 (0.10, 1.83)
0.22
5
 
0.63 (0.36, 1.10)
0.097
10
 
1.19 (0.71, 2.01)
0.50
 Oceania
1
 
0.71 (0.15, 3.32)
0.63
1
 
0.87 (0.40, 1.90)
0.70
1
 
Reference
-
 Asia
1
 
Reference
-
4
 
Reference
-
10
 
1.65 (0.96, 2.82)
0.07
Female proportion
13
Per 1%
0.79 (0.35, 1.75)
0.53
17
Per 1%
0.64 (0.25, 1.64)
0.33
40
Per 1%
0.71 (0.39, 1.29)
0.25
Mean follow-up years
13
Per 1 year
1.02 (0.99, 1.05)
0.17
17
Per 1 year
1.03 (0.99, 1.06)
0.096
40
Per 1 year
0.99 (0.97, 1.02)
0.53
CI confidence interval, IHD ischemic heart disease, OHypo overt hypothyroidism, SCH subclinical hypothyroidism
aExp (b) is the exponential of the regression coefficient and describes how the outcome variable changes with a unit increase in the explanatory variable
b P value for Exp (b)

Hypothyroidism and cardiac mortality

Of seven studies analyzed with cardiac mortality, there were 1101 events among 34,922 participants. All studies adjusted for age and sex, six adjusted for smoking, less than half adjusted for other main cardiovascular risk factors, and only one study adjusted for RT.
Evidence synthesis for cardiac mortality showed a statistically strong association with hypothyroidism (RR: 1.96; 95% CI: 1.38–2.80; Fig. 3), with moderate heterogeneity (I 2: 66.2%; P = 0.007). Sensitivity analysis by hetred command in Stata found that two outlier studies might be the source of heterogeneity [33, 34]. When the two outlier studies were removed, there was evidence of low heterogeneity in the five remaining studies (I 2: 37.9%; P = 0.17; Table 1). The heterogeneity may have been due to the smaller sample size of the outlier studies than that of the other five studies (Fig. 3).
Subgroup analyses did not find the source of heterogeneity. However, we found that the risk of cardiac mortality was also significantly higher in SCH (Table 2). Besides, we observed that cardiac patients with hypothyroidism might have a higher risk of cardiac mortality than cardiac patients with euthyroidism (RR: 2.22; 95% CI: 1.28–3.83). Sensitivity analyses with large cohorts or high-quality studies obtained similar results. Considering only seven studies in this section, we did not conduct meta-regression and funnel plots.

Hypothyroidism and cardiovascular mortality

Seventeen studies were included for cardiovascular mortality, involving 158,017 participants and 5273 events. Fourteen studies adjusted for age, thirteen adjusted for sex, more than half adjusted for cardiovascular risk factor, and only four adjusted for RT.
The summary RR of cardiovascular mortality associated with hypothyroidism was 1.11 (95% CI: 0.97–1.28; Fig. 4), with low heterogeneity (I 2: 11.1%; P = 0.324). In sensitivity analyses, the risk estimates did not change after analyzing with studies removing RT at baseline or with high-quality studies. No publication bias was found (Egger test: P = 0.92). In meta-regression and subgroup analyses, the pooled RRs of each group or subgroup were almost similar to the total.

Hypothyroidism and all-cause mortality

All-cause mortality occurred in at least 112,156 patients among 1,036,389 participants from 40 studies. Thirty-five studies adjusted for age, thirty-one adjusted for sex, most adjusted for cardiovascular risk factors, and only five adjusted for RT.
The pooled RR value of all-cause mortality was 1.25 (95% CI: 1.13–1.39; Fig. 5), with high heterogeneity (I 2: 86.9%; P < 0.001). In subgroup and meta-regression analyses, we observed evidence for heterogeneity by study population (P = 0.009). The RR for all-cause mortality in convenience samples was significantly higher than that in population-based studies; also, the risk of all-cause mortality in cardiac patients with hypothyroidism was significantly higher than that in cardiac patients with euthyroidism (RR: 1.51; 95% CI: 1.26–1.81). We observed that SCH was also associated with a higher risk of all-cause mortality (RR: 1.32; 95% CI: 1.13–1.54).
In sensitivity analyses, the pooled RR value changed little after inclusion of large cohorts, studies without RT at baseline, or high-quality studies. Sensitivity analyses by hetred command in Stata found eight outlier studies [16, 18, 19, 29, 33, 3537]. When they were removed, the pooled RRs of the remaining studies were still significant (RR: 1.30; 95% CI: 1.22–1.39; I 2 = 26.4%). No publication bias was found (Egger test: P = 0.44).

Hypothyroidism and stroke, HF, MI, AF, and total cardiovascular events

For stroke, nine studies were included, reporting 27,196 events among 761,993 participants. All studies adjusted for age, eight adjusted for sex, most adjusted for cardiovascular risk factors, and only one adjusted for RT. The overall RR of stroke was 1.09 (95% CI: 0.96–1.24; Fig. 6) with moderate heterogeneity (I 2: 52.3%; P = 0.03). After excluding one outlier study [16] with population >10,000, RR changed slightly with no heterogeneity (I 2: 0.0%; P = 0.43).
Of eight studies analyzed with HF, there were 23,033 events among 599,876 participants. Seven studies adjusted for age, all adjusted for sex, most adjusted for cardiovascular risk factors, and only two adjusted for RT. Evidence synthesis for HF did not show a significant association with hypothyroidism (RR: 1.13; 95% CI: 0.98–1.30; Fig. 6), with moderate heterogeneity across studies (I 2: 54.8%; P = 0.03). After excluding one outlier study [5], the heterogeneity decreased with the pooled RR still insignificant. We performed an additional subgroup analysis of risk of HF by mean age (Additional file 2: Table S5). The risk estimates did not significantly change in each subgroup.
Seven studies involving 588,182 participants were analyzed reporting a total of 13,263 MI. Six studies adjusted for age, four adjusted for sex, most adjusted for cardiovascular risk factors, and none adjusted for RT. Hypothyroidism was significantly associated with higher risk of MI (RR: 1.15; 95% CI: 1.05–1.25; Fig. 7), with no heterogeneity (I 2: 0.0%; P = 0.43). The same results were obtained after using fixed-effect models, inclusion of large cohorts, studies without RT at baseline, or high-quality studies.
For AF, four studies were included, reporting 18,259 events among 616,608 individuals. All studies adjusted for age and sex, most adjusted for cardiovascular risk factors, and only one adjusted for RT. The pooled RR value of AF was 1.02 (95% CI: 0.71–1.46; Fig. 7), with moderate heterogeneity (I 2: 70.6%; P = 0.02). After excluding one outlier study [38] of HIV-infected patients with a large population size, no heterogeneity was found (I 2: 0.0%; P = 0.85), but the RR was still not statistically significant.
Eight studies involving 579,969 participants were analyzed reporting a total of 45,545 total cardiovascular events. Six studies adjusted for age, six adjusted for sex, most adjusted for cardiovascular risk factors, and none adjusted for RT. The pooled RR for total cardiovascular events was 1.16 (95% CI: 0.97–1.38; Fig. 7), with moderate heterogeneity (I 2: 73.4%; P < 0.001). Similar results were observed in the sensitivity analyses.

Discussion

In this analysis of 1,898,314 participants from 55 cohort studies, hypothyroidism is associated with higher risks of IHD, MI, cardiac mortality, and all-cause mortality. These associations mostly persist in sensitivity analyses, indicating the stability of our results. In subgroup analyses, we also observe that SCH is significantly associated with higher risks of cardiac mortality (Table 2) and IHD (TSH level ≥10.0 mIU/L; Additional file 2: Table S4). Moreover, cardiac patients with hypothyroidism, compared with those with euthyroidism, have a significantly higher risk of cardiac mortality and all-cause mortality.
Our study is the first meta-analysis to evaluate risks of cardiovascular events and mortality in hypothyroidism with no restriction of hypothyroid states and study population. In subgroup analyses, our results are generally consistent with previous meta-analyses showing modest higher risks of IHD and cardiac mortality associated with SCH or SCH with TSH levels ≥10.0 mIU/L [79, 39]. However, previous meta-analyses included limited studies, and had a wider 95% CI than ours, reflecting less statistical power. Our separate analysis with MI still shows a significant higher risk in hypothyroidism, which further supports the higher risk of IHD. We observe that cardiac patients with hypothyroidism experience a significantly higher risk of cardiac mortality, but not IHD or MI, than cardiac patients with euthyroidism. There may be two reasons for this. First, small numbers of studies may weaken the reliability of the results. Second, effects of hypothyroidism on IHD events and MI might differ in different cardiac diseases, which require further prospective studies to prove.
Previous meta-analyses show conflicting results of risk of all-cause mortality in SCH. Some [810], but not all [7, 39], meta-analyses find a higher risk of all-cause mortality. Including 40 studies in all-cause mortality analyses, we find that hypothyroidism is associated with a higher risk of all-cause mortality in both the general public and patients with cardiac disease.
However, our findings could not indicate that hypothyroidism is an independent risk factor. RT might be one of the important confounders, for only a small number of cohort studies adjusted for RT (Additional file 2: Table S3). Future prospective studies should pay more attention to the RT information of each participant and adjust the results for as many confounders as possible.
We find no significant association between hypothyroidism and risks of stroke, HF, or AF. One previous IPD meta-analysis focused on risk of stroke in SCH [40]. The authors found that there was a higher risk of stroke in SCH for people younger than 65 years, but no overall effect of SCH on stroke could be demonstrated. The other IPD meta-analysis found that risks of HF events were increased with a TSH level of 10.0–19.9 mIU/L [41]. Similarly, our meta-analyses results found no overall effect of all hypothyroidism on stroke and HF. However, as stroke and HF events were secondary outcomes, we did not further conduct the subgroup analyses.
Higher risks of IHD, MI, and cardiac mortality with hypothyroidism might be associated with the known effects of thyroid hormone on the circulatory system. Altered endothelial function, increased atherosclerosis, and altered coagulability have been reported to be associated with hypothyroidism and may accelerate the development of IHD [42].
A retrospective cohort study of patients from the United Kingdom General Practitioner Research Database found that levothyroxine therapy in SCH was associated with fewer IHD events in younger individuals [43]. However, this study is observational and susceptible to residual confounding [44]. More research is needed to understand the effects of treatment of SCH.

Strengths and limitations

The strengths of this meta-analysis include strict inclusion criteria, many more cohort studies included than ever before, and predefined sensitivity and subgroup analyses. There is no publication bias, which favors stability of the findings. Moreover, we do not restrict hypothyroid states and study population, thus realizing a full-scale assessment of the effects of hypothyroidism.
There are some limitations. Firstly, heterogeneity is observed in some outcomes. However, we have found all sources of heterogeneity, and sensitivity analyses confirm the stability of our results. Secondly, the absence of IPD might influence the accuracy of the results. Thirdly, thyroid function testing was mostly performed at baseline, which would weaken the accuracy of the results regarding the possible change of thyroid function during follow-up. Another limitation is the different TSH values used across studies to define thyroid disease.

Conclusions

Our analyses suggest that hypothyroidism or SCH is a risk factor for IHD and cardiac mortality. Moreover, hypothyroidism is associated with higher risks of cardiac mortality and all-cause mortality compared with euthyroidism in both the general public and cardiac patients. Our analyses offer more reliable evidence of higher risks of IHD events and mortality in patients with hypothyroidism, and highlight that cardiac patients with hypothyroidism should be considered seriously for higher risk of cardiac mortality and all-cause mortality. However, more high-quality prospective cohort studies and randomized controlled trials are needed to draw firmer conclusions.

Acknowledgements

Not applicable.

Funding

The work was supported by the Beijing Municipal Training Foundation for Highly-qualified and Technological Talents of Health System (2014-3-038) and the Beijing Nova Program of the Beijing Municipal Science & Technology Commission (No. 2009B38).

Availability of data and materials

All data generated or analyzed during this study are included in this article and its additional files.

Authors’ contributions

YXW, ​MZ and YN conceived the idea and designed the study. YN and YJC performed the literature search. YN extracted and then YJC, LJL, and HJH independently checked the data. YN, MZ, TSZ, YJC, and HJH performed the statistical analysis. YN wrote the first draft. MZ, YXW and YN made substantial contributions to study conception and design, interpretation of results and revising the manuscript critically for intellectual content. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Not applicable.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Zusatzmaterial
Additional file 1: The PRISMA checklist. (DOC 841 kb)
12916_2017_777_MOESM1_ESM.doc
Additional file 2: Summary of included cohort studies, quality assessment, the adjusting variables in each cohort study, additional subgroup analyses by TSH levels in SCH, subgroup analysis of risk of HF by mean age, and funnel plots. (DOC 63 kb)
12916_2017_777_MOESM2_ESM.doc
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2017

BMC Medicine 1/2017 Zur Ausgabe


 

Neu im Fachgebiet Allgemeinmedizin

Meistgelesene Bücher aus dem Fachgebiet

2018 | Buch

Repetitorium Geriatrie

Geriatrische Grundversorgung - Zusatz-Weiterbildung Geriatrie - Schwerpunktbezeichnung Geriatrie

Das vorliegende Werk orientiert sich an den Fort-bzw. Weiterbildungsinhalten der Zusatz-Weiterbildung „Geriatrie“ , der Schwerpunktbezeichnung „Geriatrie“ sowie der strukturierten curricularen Fortbildung „Geriatrische Grundversorgung“ und wendet …

Herausgeber:
Dr. Rainer Neubart

2012 | Buch

Häufige Hautkrankheiten in der Allgemeinmedizin

Klinik Diagnose Therapie

Patienten mit Hautkrankheiten machen einen großen Anteil der Patienten in der Allgemeinarztpraxis aus. Prägnante Texte und zahlreiche Abbildungen zu Klinik, Pathogenese, Diagnose und Therapie helfen, die häufigsten dermatologischen Probleme zu lösen.

Autor:
Prof. Dr. med. Dietrich Abeck

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Allgemeinmedizin und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise